- Home
- SGD vs ACON Comparison
SGD vs ACON Comparison
Compare SGD & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- ACON
- Stock Information
- Founded
- SGD 2021
- ACON 2008
- Country
- SGD United States
- ACON United States
- Employees
- SGD N/A
- ACON N/A
- Industry
- SGD
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- SGD
- ACON Technology
- Exchange
- SGD Nasdaq
- ACON Nasdaq
- Market Cap
- SGD 4.4M
- ACON 4.4M
- IPO Year
- SGD N/A
- ACON 2022
- Fundamental
- Price
- SGD $0.99
- ACON $7.25
- Analyst Decision
- SGD
- ACON Buy
- Analyst Count
- SGD 0
- ACON 2
- Target Price
- SGD N/A
- ACON $22.00
- AVG Volume (30 Days)
- SGD 446.1K
- ACON 39.4K
- Earning Date
- SGD 11-14-2025
- ACON 11-14-2025
- Dividend Yield
- SGD N/A
- ACON N/A
- EPS Growth
- SGD N/A
- ACON N/A
- EPS
- SGD N/A
- ACON N/A
- Revenue
- SGD $1,536,255.00
- ACON $62,948.00
- Revenue This Year
- SGD N/A
- ACON $145.39
- Revenue Next Year
- SGD N/A
- ACON $145.45
- P/E Ratio
- SGD N/A
- ACON N/A
- Revenue Growth
- SGD 1570.24
- ACON 16.68
- 52 Week Low
- SGD $0.65
- ACON $6.20
- 52 Week High
- SGD $3.27
- ACON $3,499.51
- Technical
- Relative Strength Index (RSI)
- SGD 44.98
- ACON 38.33
- Support Level
- SGD $0.91
- ACON $7.20
- Resistance Level
- SGD $1.09
- ACON $8.00
- Average True Range (ATR)
- SGD 0.10
- ACON 0.25
- MACD
- SGD 0.00
- ACON -0.08
- Stochastic Oscillator
- SGD 60.47
- ACON 7.53
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.